New data from 33 abstracts, including one oral presentation and four late-breaking posters will be presented at the American Thoracic Society (ATS) International Conference in San Francisco, CA, US from May 18 to 21, 2025, reinforcing Sanofi’s leadership in advancing chronic respiratory disease research and addressing critical inflammatory pathways, including drivers of type 2 inflammation. Presentations related to Dupixent, which is developed in partnership with Regeneron, include notable new analyses from the BOREAS and NOTUS phase 3 studies evaluating Dupixent in patients with chronic obstructive pulmonary disease (COPD).
Alyssa Johnsen, MD, PhD
Global Therapeutic Area Head, Immunology and Oncology Development
“The breadth of data featured at ATS reinforce our ongoing commitment to leveraging immunoscience expertise in pursuit of transformative advancements in the treatment of chronic respiratory conditions. Across the Dupixent clinical program and our immunology pipeline, these results hold promise to make a positive impact on key clinical endpoints, including lung function, across chronic obstructive pulmonary disease, asthma and other diseases.”
Notable presentations across approved and pipeline medicines include:
Dupixent in COPD
New COPD data will be featured assessing the impact of Dupixent on lung function and exacerbations in COPD, including patients with or without emphysema.
- Pooled results from the pivotal landmark Phase 3 BOREAS and NOTUS studies shows Dupixent reduced exacerbations and improved lung function regardless of whether patients had emphysema.
- Additional data being presented shows that Dupixent improved multiple spirometry measures of lung function that were sustained through 52 weeks, compared to placebo.
- A late-breaking poster of a win-ratio post-hoc analysis assessed the likelihood of avoiding a composite of events including death, hospitalization, worsening symptoms and lung function decline in the COPD pivotal studies comparing Dupixent to placebo.
Safety results from both BOREAS and NOTUS COPD studies were generally consistent with the known safety profile of Dupixent in its other approved indications. In pooled data from both studies, the most common adverse events (AEs; ?2%) more frequently observed with Dupixent than placebo were viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, urinary tract infection, local administration reaction, rhinitis, eosinophilia, toothache and gastritis. In the pivotal COPD studies, the majority of patients had chronic bronchitis (?95%) and ?30% had emphysema.
Dupixent in asthma
New asthma data reinforces the impact of Dupixent on lung function and exacerbations.
- VESTIGE phase 4 study: late-breaking poster shows Dupixent reduced mucous burden, as measured by mucous plug scores and volume, and regardless of baseline fractional exhaled nitric oxide levels, as early as week 4.
- VOYAGE phase 3 study: an analysis shows that in children aged 6 to 11 years with evidence of type 2 inflammation, Dupixent reduced exacerbations and improved disease control, as measured by the proportion of patients scoring ?0.75 on the Interviewer-Administered 7-item Asthma Control Questionnaire, regardless of how long they have had disease.
The safety results in the above asthma studies were generally consistent with the known safety profile of Dupixent in moderate-to-severe asthma, with the addition of helminth infections in the VOYAGE study. In VOYAGE, the most common AEs (?5%) more frequently observed with Dupixent than placebo were nasopharyngitis, viral upper respiratory tract infections, eosinophilia and injection site reactions. In VESTIGE, the most common AEs (?5%) more frequently observed with Dupixent than placebo included COVID-19 and injection site reactions.
- LIBERTY ABPA AIRED phase 2 study: an oral presentation shows results of Dupixent on lung function, exacerbations and health-related QoL, as measured by the St. George’s Respiratory Questionnaire, in adults with allergic bronchopulmonary aspergillosis (ABPA) and asthma. ABPA is a progressive lung disease caused by hypersensitivity to a fungal microorganism that can live in the airways of patients with asthma and other breathing disorders.
Immunology pipeline
New data from Sanofi’s immunology pipeline will be featured, including new analyses evaluating rilzabrutinib in moderate-to-severe asthma, and transcriptomic data in patients with COPD to understand how combined targeting of the IL-13 and TSLP pathways may be a potential treatment approach.
- Results from a phase 2 study showing rilzabrutinib reduced loss of asthma control events in uncontrolled adult patients with moderate-to-severe asthma, as highlighted by a decrease in rescue medication use over 12 weeks.
- New data demonstrating the rationale for combined IL-13 and TSLP targeting in certain patients with COPD.
